A detailed history of Affinity Asset Advisors, LLC transactions in Verona Pharma PLC stock. As of the latest transaction made, Affinity Asset Advisors, LLC holds 650,000 shares of VRNA stock, worth $29.4 Million. This represents 3.23% of its overall portfolio holdings.

Number of Shares
650,000
Previous 700,000 7.14%
Holding current value
$29.4 Million
Previous $10.1 Million 84.75%
% of portfolio
3.23%
Previous 1.38%

Shares

9 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$15.46 - $30.16 $773,000 - $1.51 Million
-50,000 Reduced 7.14%
650,000 $18.7 Million
Q2 2024

Aug 14, 2024

SELL
$11.48 - $17.02 $1.35 Million - $2.01 Million
-117,833 Reduced 14.41%
700,000 $10.1 Million
Q1 2024

May 14, 2024

BUY
$15.3 - $20.24 $3.89 Million - $5.14 Million
254,009 Added 45.05%
817,833 $13.2 Million
Q4 2023

Feb 13, 2024

BUY
$11.94 - $20.47 $2.33 Million - $4 Million
195,495 Added 53.08%
563,824 $11.2 Million
Q3 2023

Nov 14, 2023

SELL
$16.3 - $22.09 $1.29 Million - $1.75 Million
-79,338 Reduced 17.72%
368,329 $6 Million
Q2 2023

Aug 14, 2023

SELL
$19.41 - $23.43 $100,039 - $120,758
-5,154 Reduced 1.14%
447,667 $9.46 Million
Q1 2023

May 15, 2023

BUY
$18.06 - $25.27 $2.53 Million - $3.55 Million
140,323 Added 44.9%
452,821 $9.09 Million
Q4 2022

Feb 13, 2023

SELL
$9.84 - $26.13 $369,019 - $979,927
-37,502 Reduced 10.71%
312,498 $8.17 Million
Q3 2022

Nov 14, 2022

BUY
$4.14 - $13.59 $1.45 Million - $4.76 Million
350,000 New
350,000 $3.58 Million

Others Institutions Holding VRNA

About Verona Pharma plc


  • Ticker VRNA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 60,954,200
  • Market Cap $2.76B
  • Description
  • Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodi...
More about VRNA
Track This Portfolio

Track Affinity Asset Advisors, LLC Portfolio

Follow Affinity Asset Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Affinity Asset Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Affinity Asset Advisors, LLC with notifications on news.